Which of the following is NOT listed as an IL-23 inhibitor for enteropathic arthritis in the source material?

Which of the following is NOT listed as an IL-23 inhibitor for enteropathic arthritis in the source material?

• A. Guselkumab
• B. Tidrakizumab
• C. Risankixumab
• D. Adalimumab

Answer: (D)

IL-23 inhibitors work by blocking the p19 subunit of IL-23, dampening the Th17 inflammatory pathway that fuels enteropathic arthritis. The drugs guselkumab, tildrakizumab, and risankizumab are all anti-IL-23 antibodies, so they fit this category. Adalimumab, however, targets TNF-α, not IL-23, so it does not belong to the IL-23 inhibitor class. That’s why it’s the option that is not listed as an IL-23 inhibitor.

IL-23 inhibitors work by blocking the p19 subunit of IL-23, dampening the Th17 inflammatory pathway that fuels enteropathic arthritis. The drugs guselkumab, tildrakizumab, and risankizumab are all anti-IL-23 antibodies, so they fit this category. Adalimumab, however, targets TNF-α, not IL-23, so it does not belong to the IL-23 inhibitor class. That’s why it’s the option that is not listed as an IL-23 inhibitor.